Stabilization of alpha -Synuclein Secondary Structure upon Binding to Synthetic Membranes*

W. Sean DavidsonDagger , Ana JonasDagger , David F. Clayton§, and Julia M. George§

From the Dagger  Department of Biochemistry, University of Illinois, Urbana, Illinois 61801 and the § Department of Cell and Structural Biology, University of Illinois, Urbana, Illinois 61801

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

alpha -Synuclein is a highly conserved presynaptic protein of unknown function. A mutation in the protein has been causally linked to Parkinson's disease in humans, and the normal protein is an abundant component of the intraneuronal inclusions (Lewy bodies) characteristic of the disease. alpha -Synuclein is also the precursor to an intrinsic component of extracellular plaques in Alzheimer's disease. The alpha -synuclein sequence is largely composed of degenerate 11-residue repeats reminiscent of the amphipathic alpha -helical domains of the exchangeable apolipoproteins. We hypothesized that alpha -synuclein should associate with phospholipid bilayers and that this lipid association should stabilize an alpha -helical secondary structure in the protein. We report that alpha -synuclein binds to small unilamellar phospholipid vesicles containing acidic phospholipids, but not to vesicles with a net neutral charge. We further show that the protein associates preferentially with vesicles of smaller diameter (20-25 nm) as opposed to larger (~125 nm) vesicles. Lipid binding is accompanied by an increase in alpha -helicity from 3% to approximately 80%. These observations are consistent with a role in vesicle function at the presynaptic terminal.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Our studies in songbird brain resulted in the identification of a presynaptic protein, which we called synelfin, whose expression is regulated in the avian song control circuit during the critical period for song learning (1). We hypothesized that this protein might play an important role in the modulation of synaptic plasticity, and have focused on determining its normal cellular and biochemical function.

Independent evidence has emerged that implicates this protein in human neurodegenerative disease. Ueda et al. (2) reported that a fragment of the homologous human protein is an intrinsic component of the amyloid plaques which deposit extracellularly in the brains of individuals with Alzheimer's disease; they called the protein NACP,1 for non-amyloid component precursor. More recently, Polymeropoulos et al. (3) described a mutation in the identical protein alpha -synuclein, which apparently causes a hereditary form of Parkinson's disease. This neurodegenerative disease is also characterized by the abnormal deposition of cellular material, in this case the intracellular inclusions known as Lewy bodies (4), and these structures are also immunopositive for alpha -synuclein (5).

Synelfin/alpha -synuclein/NACP (which we will henceforth refer to as alpha -synuclein) is a small, soluble protein of 140-143 amino acids which is highly enriched in presynaptic nerve terminals (1, 6, 7). The mechanism of its localization is unclear, however, because unlike most presynaptic proteins, alpha -synuclein is not tightly associated with either the synaptic vesicle or the synaptic plasma membrane (1, 8). The alpha -synuclein sequence has been extremely well conserved in evolution (1, 8, 9), implying functional constraints on its three-dimensional structure. Paradoxically, its conformation in solution appears to be largely random, as estimated from circular dichroism measurements (10).

The most notable feature of the sequence is a recurring 11-residue periodicity, which is consistent with the capacity to fold into an amphipathic alpha -helix (1). When projected onto a helical wheel (11), several of the alpha -synuclein 11-mers display a distinctive distribution of polar and nonpolar residues to opposite faces of the helix, which conforms very well to the consensus class A2 amphipathic alpha -helix, found in the lipid-binding domains of the exchangeable apolipoproteins A-II, C-I, C-II, and C-III (12, 13). Observation of this structural motif led us to hypothesize that: 1) alpha -synuclein would have the capacity to associate with phospholipid membranes, and 2) membrane association would be dependent upon an alpha -helical secondary structure. Here we show data in support of both of these hypotheses. Furthermore, we demonstrate that, in contrast to the exchangeable apolipoproteins, alpha -synuclein binds exclusively to acidic phospholipids and preferentially to vesicles with smaller diameters. These observations suggest that the secondary structure of alpha -synuclein might be sufficient to target it to a particular subset of vesicles in the presynaptic terminal, perhaps facilitating selective regulation of some aspect of vesicle function.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials

Bovine brain phospholipid extract (Folch extract 1) and egg ovalbumin were purchased from Sigma (+99% grade). 1-Palmitoyl 2-oleoyl phosphatidylcholine (POPC), 1-palmitoyl 2-oleoyl phosphatidic acid (POPA), 1-palmitoyl 2-oleoyl phosphatidylserine (POPS), 1-palmitoyl 2-oleoyl phosphatidylethanolamine (POPE), and liver phosphatidylinositol (PI) were obtained from Avanti Polar Lipids (Birmingham, AL). All other reagents were analytical grade.

Methods

Purification of Recombinant alpha -Synuclein-- The canary alpha -synuclein cDNA was subcloned into the plasmid pET28a (Novagen), which directs expression in Escherichia coli via an isopropyl-1-thio-beta -D-galactopyranoside-inducible T7 promoter. Purification of alpha -synuclein was based on a modification of Weinreb et al. (10), who documented the heat stability of the protein; briefly, cell lysates are boiled, and the soluble fraction is precipitated with 60% ammonium sulfate. The pellet is resuspended in 25 mM Tris, pH 9.0, loaded onto a Poros HQ column (Perseptive Biosystems), and eluted with 0-1 M NaCl. alpha -Synuclein containing fractions are pooled and exchanged into sodium acetate buffer, pH 4.0, loaded onto a Poros HS column (Perseptive Biosystems), and eluted with 0-1 M NaCl. alpha -Synuclein fractions are finally loaded onto a gel exclusion column (Superose 6, Pharmacia) to confirm purity and achieve final buffer exchange.

The Binding of alpha -Synuclein to Small (SUV) and Large (LUV) Unilamellar Vesicles-- SUV of various lipid compositions were prepared by the sonication technique of Barenholz et al. (14). The SUV were reisolated by ultracentrifugation at 55,000 rpm in a TLA 100.3 rotor for 2 h at 25 °C and exhibited hydrodynamic diameters of 25 ± 5 nm as estimated by gel filtration chromatography (15). LUV were prepared as described by Hope et al. (16). Briefly, phospholipid multilamellar liposomes in buffer were placed into an extrusion device (Lipex Biomembranes Inc., Vancouver, British Columbia, Canada) which passed the mixture through polycarbonate filters of 100-nm pore size under pressures of 100-500 p.s.i. This procedure routinely produced unilamellar vesicles with hydrodynamic diameters of 125 ± 30 nm. SUV or LUV preparations in Tris buffer were mixed with alpha -synuclein to determine the affinity of alpha -synuclein for lipid surfaces of varying curvature. The vesicles and alpha -synuclein at a 20:1 mass ratio of phospholipid to alpha -synuclein were incubated in Tris buffer for 2-24 h at 25 °C. The resulting complexes were separated from unreacted lipid and protein on a calibrated Superose 6 (10 mm × 30 cm) gel filtration column (Pharmacia) eluted at 0.5 ml/min with Tris buffer. The protein content of the fractions was determined using the Markwell modification of the Lowry protein assay (17) while phospholipids were determined as inorganic phosphorus by the method of Sokoloff and Rothblat (18). In some experiments, the fractions corresponding to lipid-free protein, SUV and any multilamellar vesicles were pooled and analyzed by immunoblotting with alpha -synuclein monoclonal H3C, as described in Ref. 1.

Secondary Structure Analysis-- The structural predictions based on the primary sequence of canary alpha -synuclein (1) were determined using programs ANTHEPROT (19) and the Wisconsin Sequence Analysis program (Genetics Computer Group) running on an IBM PC. Three algorithms, the Levin homologue method (20), the GOR 1 prediction method (21), and the Chou-Fasman prediction method (22) were used for the sequence analysis because of their distinct prediction strategies. Consensus predictions were obtained from the results of all three methods by manual comparison of the predictions for each amino acid in the sequence (see the legend to Fig. 5 for more detail). For more information on the application of these established prediction methods to lipid-binding proteins, see Ref. 23.

Circular Dichroism Measurements and Analysis-- The average secondary structure contents of lipid-free and lipid-bound alpha -synuclein were determined by circular dichroism (CD) spectroscopy using a Jasco J-720 spectropolarimeter. Spectra were taken at 25 °C in a 0.1-cm path length quartz cuvette containing the sample at concentrations of 0.1-0.2 mg/ml of protein in 20 mM phosphate buffer, pH 8.0, without NaCl. The spectra were corrected for buffer and vesicle contributions as appropriate. The percent alpha -helix was determined from the molar ellipticities at 222 nm (42) as well as by computer fitting to a library of CD spectra from proteins of known structure using the learning neural network program K2D which is based on the algorithm published by Andrade et al. (24).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Characterization of alpha -Synuclein with Respect to Apolipoproteins-- The identification of several predicted class A2 amphipathic alpha -helices in the alpha -synuclein sequence suggested that alpha -synuclein might exhibit traits that are characteristic of the plasma apolipoproteins. Experiments showed that recombinant alpha -synuclein could not clear multilamellar dimyristoylphosphatidylcholine liposomes, whereas apoA-I readily cleared them into small disc-shaped particles (data not shown). Furthermore, alpha -synuclein did not yield protein-lipid complexes using the sodium cholate method of reconstituted high density lipoprotein preparation commonly used with apoA-I (data not shown). Finally, studies using the chemical cross-linking agent BS3 failed to demonstrate self-association of alpha -synuclein when free in solution (not shown), a common observation with apolipoproteins. Taken together, these results indicate that despite similarities in predicted structure, alpha -synuclein does not possess the critical properties of apolipoproteins.

However, numerous data document a tendency of alpha -synuclein to colocalize with synaptic vesicles in vivo (6, 25, 26), and the presence of predicted lipid-binding helices suggests a lipid association. We decided to try SUV, which are relatively homogeneous, can be analyzed by gel exclusion chromatography, have sizes in the range of synaptic vesicles, and are compatible with circular dichroism as a means of estimating protein secondary structure. SUV were prepared from a commercially available brain phospholipid extract (Folch fraction I, Sigma) or synthetic POPC, and incubated with recombinant alpha -synuclein for 2-24 h at room temperature. The incubation mixture was then separated into various size components by gel filtration chromatography (Fig. 1). The resulting fractions were analyzed for protein and phospholipid content. The phospholipid profile from the column runs routinely showed two size populations. The earlier peak (fractions 17-19) was due to large multilamellar vesicles (MLV), whereas the later peak (centered around fraction 25) was due to SUV that were about 20-25 nm in diameter (15). 70% of the alpha -synuclein that was incubated with brain extract vesicles remained associated with the SUV while the remainder eluted at a volume that was characteristic of the free protein. No alpha -synuclein was found in the MLV fractions (Fig. 1A). In contrast, alpha -synuclein did not associate with the synthetic POPC SUV; 100% of the protein eluted in the lipid-free form. Control incubations were performed using egg ovalbumin which has no known lipid surface activity (Fig. 1, B and D). Ovalbumin did not associate with either type of vesicle, indicating that the association of alpha -synuclein with the brain extract vesicles shown in Fig. 1A was not due to nonspecific association or trapping of the protein molecules within the vesicles.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   Phospholipid binding assay. Vesicles composed of either a brain phospholipid extract (Folch fraction I) or POPC were incubated with recombinant canary alpha -synuclein or chicken ovalbumin for 2 h at room temperature, and separated by gel exclusion chromatography. Fractions were assayed independently for protein (filled circles) and phospholipid content (open circles). A, alpha -synuclein and B, ovalbumin with brain phospholipid extract; C, alpha -synuclein and D, ovalbumin with POPC. The phospholipid peak centered around fraction 25 represents small unilamellar vesicles (15), while the peak centered around fraction 18 represents larger multilamellar vesicles. Lipid-free alpha -synuclein and ovalbumin elute in fractions 33-40; this is also observed with incubations containing no vesicles (not shown).

Lot analysis indicated that Sigma brain extract I contained 50-55% phosphatidylserine (PS), 10-12% PI, and 10% phosphatidylethanolamine (PE), with 23-30% unknown phospholipids. Both PS and PI have a net negative charge compared with PE and PC, which have no net charge. To determine if the presence of the acidic lipids was responsible for the preferential binding of alpha -synuclein to BE1 vesicles versus POPC vesicles, we performed a series of incubations using vesicles composed of 1:1 (w/w) mixtures of purified phospholipids. The incubations were performed exactly as those in Fig. 1. After separation on the column, the fractions corresponding to MLV, SUV, and lipid-free protein peaks were pooled. Equal fractions of each of the pooled peaks were run on an SDS gel and then immunoblotted with the H3C monoclonal antibody to the C terminus of alpha -synuclein (1) (Fig. 2). In the absence of phospholipid, all of the alpha -synuclein appeared in the lipid-free fraction as expected. alpha -Synuclein did not bind to SUV or MLV composed of PC only, nor did it bind to a 1:1 mixture of PC and PE. However, when acidic lipids such as PS, phosphatidic acid (PA), and PI were mixed with either PC or PE, significant amounts of alpha -synuclein eluted in the SUV fractions but not in the MLV fractions. In the cases of the PA and PI containing vesicles, close to 100% of the alpha -synuclein was found in the SUV fractions whereas in the case of the PS containing vesicles 10-15% of the alpha -synuclein remained in the lipid-free fractions. The alpha -synuclein-vesicle complexes were found to be stable for at least 2 weeks at room temperature. Separate experiments were performed to determine the relative amount of acidic lipid to PC required for efficient alpha -synuclein binding to SUV. Acidic lipid concentrations of 30-50% of the vesicle weight were required to approach 100% binding under these conditions (data not shown). As the acidic lipid content was reduced to 20% or less, increasing amounts of alpha -synuclein appeared in the lipid-free form. The incubation with the PI-containing vesicles appeared to produce covalently linked oligomers of alpha -synuclein when analyzed by SDS-polyacrylamide gel electrophoresis (Fig. 2). The cause of this is not clear, although it is possible that products of lipid peroxidation may be responsible for protein cross-linking. The PI used in these experiments was purified from bovine liver whereas the other lipids were synthetic, monounsaturated lipids that are resistant to lipid oxidation.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   Selectivity for acidic phospholipids. Vesicles were prepared from various mixtures of acidic and neutral phospholipids, incubated with canary alpha -synuclein, and separated as in Fig. 1. Peaks representing MLV, SUV, and free protein were collected, and equal fractions of each peak were analyzed by immunoblot with monoclonal H3C to the alpha -synuclein C terminus. The first panel represents protein alone; subsequent panels represent protein incubated with vesicles composed of POPC or various 1:1 mixtures of POPC, POPE, POPS, POPA, or bovine liver PI, as indicated. The 45-kDa species which is observed in the PI incubation is reproducible (not shown) and is of the appropriate size for a homodimer.

The results shown in Fig. 2 demonstrate that alpha -synuclein can bind to SUV which contain negatively charged phospholipids. These data suggested a greater affinity for the SUV versus the MLV, but since the larger vesicles are multilamellar (with a smaller proportion of lipid accessible for surface binding) this observation was inconclusive. To determine whether alpha -synuclein has a similar affinity for more planar, less curved lipid surfaces, the binding of alpha -synuclein to LUV was compared with that of the SUV. We chose lipid compositions of either PC/PA (1:1) or PC alone, since these gave the most and least alpha -synuclein binding, respectively, in the SUV experiments. The LUV had hydrodynamic diameters of 125 ± 30 nm, whereas the SUV measured 20-25 nm. The results are shown in Table I. alpha -Synuclein did not bind to vesicles that contained only PC, regardless of size. In the case of the PC/PA vesicles, binding to the LUV was less than to the SUV in incubations with identical input amounts of protein and phospholipid. This result indicate that alpha -synuclein has a higher affinity for smaller vesicles with highly curved surfaces but will still bind more planar surfaces as long as acidic phospholipids are present.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Comparison of alpha -synuclein binding to unilamellar phospholipid vesicles of different size

The observed requirement for acidic phospholipids suggests that ionic interactions may occur between the protein and the lipid surface. To determine the importance of such interactions, alpha -synuclein was incubated with PC/PA vesicles under conditions of increasing NaCl concentration. Fig. 3 shows a plot of the SUV data. The amount of alpha -synuclein binding decreased somewhat with increasing ionic strength, but binding was not abolished even at 750 mM NaCl. This result suggests that ionic interactions play a role in the surface binding process, but the fact that binding could not be further inhibited indicates that additional forces must also help stabilize the protein-lipid interaction.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Ionic strength dependence of lipid association. alpha -Synuclein was incubated with small unilamellar vesicles composed of POPC/POPA (1:1) and varying concentrations of NaCl, then separated by gel exclusion chromatography as in Fig. 1. Peak fractions representing small unilamellar vesicles were pooled and analyzed for protein and phospholipid content. The quantity of bound protein per milligram of phospholipid is plotted as a function of the NaCl concentration. Data points represent one experiment done in triplicate (n = 3). Error bars for the 250 mM data point are too small to represent on the graph.

Structural Analysis of alpha -Synuclein in the Lipid-free and Lipid-bound States-- Circular dichroism spectroscopy was used to determine the effects of lipid binding on the secondary structure of alpha -synuclein. The spectrum of lipid-free alpha -synuclein is shown in Fig. 4A. The prominent minimum ellipticity at 200 nm was characteristic of a high percentage of random coil. Table II lists the predicted secondary structure compositions based on the CD spectrum from 200 to 241 nm. The data indicate that lipid-free alpha -synuclein is highly unstructured in solution. This is in strong agreement with the results of Weinreb et al. (10) for human alpha -synuclein. Upon lipid binding, alpha -synuclein undergoes a striking change in conformation (Fig. 4A, Table II), shifting to a highly alpha -helical conformation as evidenced by the characteristic minima at 208 and 222 nm. The helical character of the protein increased from less than 3% to greater than 71% alpha -helix when bound to lipid. A similar change in conformation was observed when alpha -synuclein bound to PC/PS vesicles (Fig. 4B), although the helical content was not as high as in the case of the PC/PA vesicles. This difference is due to the spectral contribution of lipid-free alpha -synuclein, which was present only in the PC/PS incubations (see Fig. 2). The incubation of alpha -synuclein with PC-only vesicles resulted in a CD spectrum that resembled lipid-free alpha -synuclein, confirming that alpha -synuclein did not bind to these vesicles. The secondary structure content of alpha -synuclein bound to PC/PA vesicles was also measured under conditions of increasing ionic strength. Table III shows that as the NaCl concentration was increased, the degree of alpha -helix content decreased with a corresponding increase in the estimated amount of random coil content. These changes in structure generally correlated with the decreases in alpha -synuclein binding shown in Fig. 3. In a single experiment with a small amount of recombinant human NACP/alpha -synuclein (a kind gift of Peter Lansbury), we observed a qualitatively similar increase in alpha -helical content when the protein associated with PC/PA vesicles (data not shown).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4.   Circular dichroism spectra of recombinant alpha -synuclein in the lipid-free form and after incubation with various SUV. Samples were prepared in 50 mM phosphate buffer, pH 7.6, at 100 µg/ml. The molar ellipticity was measured at 25 °C in a 0.1-cm path length quartz cell. Panel A shows alpha -synuclein either alone (filled squares) or after incubation with 1:1 POPC/POPA (w/w) small unilamellar vesicles for 2-24 h at 25 °C at a 1:20 weight ratio of alpha -synuclein to phospholipid (filled circles). Panel B shows alpha -synuclein incubated with POPC-only SUV (open squares) and with 1:1 POPC/POPS vesicles (open circles). The spectra shown are averaged from two separate experiments each done in triplicate (n = 6).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Circular dichroism evaluation of the secondary structure of recombinant human alpha -synuclein in the lipid-free state and bound to SUVs of varying composition

                              
View this table:
[in this window]
[in a new window]
 
Table III
Circular dichroism evaluation of the secondary structure of recombinant human alpha -synuclein bound to PC/PA SUV in response to increasing ionic strength

To determine the regions of alpha -synuclein that undergo lipid-induced structural changes, we first performed computer-generated secondary structure predictions using the primary sequence of the protein. Three structural prediction algorithms (see "Methods") varied in their estimates of overall secondary structure (not shown), with consensus values of 56% alpha -helix, 10% beta -sheet, 0% turn, 27% random coil, and 7% undetermined. These values differ significantly from estimates based on circular dichroism measurements in either the presence or absence of vesicles (Table II), probably because the algorithms do not adequately model the stabilization of secondary structure by associated lipid, which appears to be critical in the case of alpha -synuclein. For this reason, a modelling strategy was applied which was originally developed for analysis of the exchangeable apolipoproteins (13). Like the apolipoproteins, much of the alpha -synuclein sequence is composed of repetitions of a degenerate 11-mer sequence which can form an amphipathic alpha -helix with a conserved arrangement of acidic, basic, and hydrophobic residues (1). We subjected the entire alpha -synuclein sequence to helical wheel analysis, and identified 5 potential amphipathic alpha -helices which encompass all of the 11-mer repeats and some adjacent amino acid residues; these are illustrated in Fig. 5.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 5.   Helical wheel analysis of alpha -synuclein structure. The alpha -synuclein sequence was projected radially at 100° intervals (11) to determine the distribution of charged residues along an idealized alpha -helix. Nonpolar residues are shaded black, polar residues are gray, and charged residues are unshaded. Residues predicted to be helix breaking are boxed and indicated by an asterisk (*); helices are assumed to terminate on the prior residue. The angle subtended by the nonpolar face is indicated by a dashed line, and the center of the nonpolar face by an arrow. A, helix 1, residues 1-15 plus terminating residue Val-16; B, helix 2, residues 17-37 plus terminating residue Leu-38; C, helix 3, residues 39-48 plus terminating residue Val-49; D, helix 4, residues 50-60; E, helix 5, residues 61-93, plus terminating residue Leu-94. Note that for helix 5, the polar/nonpolar interface is not demarcated by basic residues as in helices 1-4.

Helices 1-4 (residues 1-60) conform to the class A2 consensus (see "Discussion"), distinguished by clustered basic residues at the polar/nonpolar interface and positioned ± 100° from the center of the nonpolar face; a preponderance of lysine relative to arginine among these basic residues; and several glutamate residues localized to the polar face. Segrest et al. (13) defines several amphipathic alpha -helix-terminating amino acids: 1) Pro at any position; 2) Phe, Met, Ile, Leu, Val, Trp, or Cys within 40° of the center of the polar face; 3) Lys, Arg, Glu, or Asp within 40° of the center of the nonpolar face; 4) Gln or Asn within 20° of the center of the nonpolar face, or a cassette of four or more of the neutral or polar residues Thr, Gly, Ser, His, Gln, and Asn. Helices 1-3 are terminated by residues meeting criterion 2 (Val-16, Leu-38, and Val-49). Although no helix-breaking residues occur between residues 50 and 94 according to the rules of Segrest et al. (13), helix 4 (residues 50-60) and helix 5 (residues 61-94) are plotted separately because the distinctive charge distribution of a class A2 helix is not maintained beyond residue 60. Instead, helix 5 displays a random radial distribution of charged residues to the polar face, which is similar to the class G* helix of Segrest et al. (13). Helix 5 is terminated by Leu-94, according to criterion 2. The remainder of the alpha -synuclein sequence is non-amphipathic, but the structural predictions algorithms suggest that residues 95-111 and 133-143 also have the propensity to form alpha -helices that might be indirectly stabilized by lipid binding. This analysis predicts an overall alpha -helix content of 83%, 63% contributed by the five amphipathic helices, and an additional 20% from the C terminus. This correlates well with the % alpha -helix estimated by CD for lipid-bound alpha -synuclein. Our structural predictions are summarized in Fig. 6, along with the primary sequences of canary and human alpha -synuclein. Note that differences between the two sequences conserve the 5 helices, the putative helix-breaking residues, and the acidic C terminus.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 6.   Diagrammatic summary of alpha -synuclein structure. The primary sequence of canary alpha -synuclein is shown; differences in the human sequence are indicated by either the substituted residue or - to represent a deletion. The seven 11-residue repeats are indicated above the primary sequence. The five candidate helices derived in Fig. 5 are represented as boxes; * represents non-amphipathic residues either punctuating the helices or in the C terminus.

Additional computer analysis using the algorithm of Geourjon and Deleage (19) found that the potential helical segments within alpha -synuclein were not predicted to be transmembrane helices (not shown). This suggests that alpha -synuclein interacts with lipid surfaces by virtue of the hydrophobic faces of amphipathic helices and not by threading helical segments through the bilayer.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

alpha -Synuclein binds best to vesicles containing at least 30% acidic phospholipid. Because the requirement for acidic phospholipid was determined at a lipid/protein mass ratio of 20:1 (molar ratio ~400:1), there must be an excess of acidic sites available even at 20% acidic phospholipid, suggesting that binding requires multiple interactions.

A preference for acidic phospholipids could be a mechanism for targeting the protein to a particular membrane or vesicle population. Synuclein was first isolated from the electric fish Torpedo because of its association with the abundant cholinergic vesicles of that animal's electric organ, essentially a massive synapse (25), and EM immunohistochemistry suggests that the protein is concentrated in the cytoplasmic matrix surrounding synaptic vesicles in the presynaptic terminal (25, 27). Our studies of primary hippocampal neurons show a tight colocalization of alpha -synuclein with the synaptive vesicle protein synapsin by immunofluorescence, further indication that the protein associates with this vesicle population (6). However, in subcellular fractionation experiments, alpha -synuclein does not tightly copurify with synaptic vesicles, and the majority of alpha -synuclein in cytosolic and synaptosomal subfractions is freely soluble (1, 8, 26). This paradoxical feature of alpha -synuclein could result from rapid exchange of the protein between membrane surface and cytosol, modulated by factors that have yet to be identified.

The average composition of synaptic vesicles is estimated to be 0-2% PA, 40-48% PC, 24-36% PE, 4-12% sphingomyelin, 7-12% PS, 3-4% PI, with a cholesterol:phospholipid ratio of ~0.5-0.6 (28-30); the proportion of acidic phospholipids (10-18%) is somewhat less than the 30% acidic phospholipid required for maximal binding of alpha -synuclein to our synthetic membranes. However, these estimates of composition do not take into account the asymmetric distribution of phospholipid species between the two leaflets of the membrane, a critical property of many biological membranes, including synaptic vesicles. Determination of phospholipid asymmetry in synaptic vesicles has been somewhat confounded by methodological concerns, but it is estimated that 100% of the PI in synaptic vesicles is localized to the cytoplasmic face (30). Also, it is increasingly clear that phospholipids can become locally concentrated within a single membrane leaflet, with important consequences for protein localization. For example, microdomains of PS form in response to increased [Ca2+], encouraging translocation and activation of protein kinase C (31). Bilayer asymmetry and/or phospholipid microdomains might be critical to alpha -synuclein localization in vivo, yet difficult to reproduce in vitro.

The observation that alpha -synuclein binds small (20-25 nm) in preference to large (~125 nm) unilamellar vesicles of the same composition most likely results from differences in phospholipid packing on the vesicle surface. The phospholipid bilayer of an LUV is an essentially planar surface in which the fatty acyl side chains are motionally restricted (32), compared with the curved surface of an SUV (33). It has been demonstrated that the initial insertion of the amphipathic alpha -helical regions of plasma lipoproteins into a phospholipid bilayer is facilitated by the existence of lipid packing defects caused by extreme membrane curvature or by the differential packing properties of different phospholipids within the membrane (34). It is likely that these factors also affect the partitioning of alpha -synuclein between the lipid-bound and lipid-free states. This observation may be important for in vivo targeting of alpha -synuclein to vesicles or membranes with irregular or curved surfaces.

The binding of alpha -synuclein to acidic phospholipid vesicles (PC/PA or PC/PS) is accompanied by a large increase in its alpha -helical content; no such increase is observed in the presence of PC vesicles, to which alpha -synuclein does not bind (Table II). alpha -Helicity declines in parallel with lipid binding as salt concentration is increased (Table III). These observations suggest that lipid binding is mediated by alpha -helical structures which are themselves stable only in the presence of lipid, and are consistent with our initial identification of consensus domains for lipid-binding amphipathic alpha -helices in the alpha -synuclein sequence (1). We have now extended our analysis of the alpha -synuclein sequence, and have identified 5 potential amphipathic alpha -helical domains representing 2 different classes, in accordance with the criteria established by Segrest et al. (13) for analysis of the exchangeable apolipoproteins.

A key feature of the alpha -synuclein peptide sequence is a set of 7 degenerate 11-residue repeats. 11-mer repeats are also a hallmark of the amphipathic alpha -helices of the exchangeable apolipoproteins, which mediate a variety of lipid and protein interactions. These alpha -helices are divided into classes depending upon the distribution of residues to the polar and nonpolar faces of the helices (13). Class A helices are typically lipid-binding, and are characterized by a clustering of basic residues at the polar/nonpolar interface and acidic residues at the center of the polar face. Class G* helices are implicated in protein interactions; this class is less well defined and is typically characterized by a random radial distribution of charged residues to the polar face of the helix. Class Y helices (which are rare) also mediate lipid interactions (35, 36), and are characterized by 2 clusters of negative residues separating 3 clusters of positive residues on the polar face of the helix.

Class A helices are further subdivided as class A1, A2, or A4. Class A4 is least common and is distinguished by clusters of basic residues ±120° from the center of the nonpolar face. Class A1 helices typically have arginines positioned ±90° from the center of the nonpolar face, with leucines at the center of the nonpolar face. Class A2, the motif which is best defined and correlated with the highest lipid affinity, is characterized by lysines positioned ±100° from the center of the nonpolar face, and glutamates clustered in the center of the polar face. Segrest et al. (12) proposed a model for the interaction of class A helices with phospholipid membranes, wherein positively charged lysine or arginine residues positioned at the polar/nonpolar interface interact with negatively charged phosphate groups in the phospholipid backbone. The amphipathicity of these amino acid residues, particularly lysine with its longer aliphatic side chain, allows the hydrophobic face of the helix to penetrate more deeply into the bilayer interior, stabilizing the lipid-protein interaction (12).

Helices 1-4 of alpha -synuclein are clearly class A, and most resemble the class A2 consensus in the positioning of the interfacial basic residues at ±100° from the center of the nonpolar face, in the preponderence of lysines over arginines, and in the presence of glutamate residues on the polar face. These domains would be predicted to mediate the binding of alpha -synuclein to phospholipid bilayers. Helix 5 resembles the class G* helix, and thus is a candidate for protein-protein interactions. Interestingly, this putative helix (residues 61-93) corresponds almost exactly to the non-amyloid component peptide (residues 61-95) purified from the Alzheimer's senile plaque.

A few notable features distinguish the putative amphipathic alpha -synuclein helices from those in the exchangeable apolipoproteins. The threonine residues at the center of the nonpolar faces of helices 2-4 are unique to alpha -synuclein and are perfectly conserved among sequences from canary, human, and rat (1), which might represent a site for regulation by phosphorylation. Threonine, although polar, can reside on the nonpolar face of the helix due to its relatively long aliphatic side chain (13). Phosphorylation of these residues would introduce negative charges which would be expected to disrupt lipid binding. Evidence exists that a closely related isoform of this protein, beta -synuclein, is phosphorylated in vivo and in vitro (37), although the precise sites remain to be mapped.

Another unique aspect of the alpha -synuclein sequence is the absence of prolines among the 11-mer repeating domains. The amphipathic alpha -helical motifs of the exchangeable apolipoproteins are typically divided into anti-parallel 22-residue segments by proline residues, which introduce helix-breaking hairpin turns. The resulting short helical segments function cooperatively, and this cooperativity enhances many of the functions of the apolipoproteins, including their dynamic ability to bind and solubilize lipid particles (for a review, see Ref. 13) In contrast, the alpha -synuclein helices 1-4 seem to be punctuated at various points by nonpolar residues that are predicted to disrupt the amphipathicity of a helix (Fig. 6). It is not known whether these residues mediate breaks to form distinct helices or merely introduce kinks that do not totally disrupt a single, long helix.

Borhani et al. (38) have recently solved the x-ray crystal structure of a fragment of apoA-I. These authors suggest that the helices in apoA-I are not arranged in an antiparallel fashion when associated with spherical lipid particles, in contrast with the evidence for an antiparallel orientation in discoidal particles (39). The intrahelical regions in this model form kinks that are significantly less than 180° which allows the protein to wrap around the sphere of lipid in a ring or horseshoe topology. Thus, apoA-I may have the ability to adjust the degree of turn between adjacent helical segments, with turns approximating 180° in discs but of lesser degree in spherical particles.

The absence of proline-induced hairpin turns may explain why alpha -synuclein can bind spherical and planar surfaces, yet fail to form discoidal particles. It should be noted that among the many protein/lipid incubations performed in the course of the work described here, we never detected structures in the size range of discs (7-12 nm). In addition, alpha -synuclein failed to clear multilamellar dimyristoylphosphatidylcholine liposomes, which are readily cleared into discoidal particles by apoA-I (data not shown), and did not form discs using the sodium cholate dialysis method, which is well established for the preparation of reconstituted high density lipoprotein with apoA-I (data not shown).

Clearly, identification of the physiological substrates for alpha -synuclein binding will be critical to discerning its function in vivo. It is interesting to note that the class A helices are typically stabilizing to membranes, inhibiting membrane fusion and lysis by relieving negative monolayer curvature strain (40, 41). Whether alpha -synuclein exerts similar stabilizing effects on its target membrane, e.g. to modulate some aspect of vesicle trafficking, remains a question for future research. The very dynamic structure of alpha -synuclein in response to its environment will likely be important in understanding its propensity to aggregate and accumulate in both Alzheimer's and Parkinson's diseases.

    ACKNOWLEDGEMENTS

We thank Dr. Wendi Rodrigueza for providing LUV and Wendy Woods and Michael Urban for invaluable technical assistance.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant 1R01 AG13762.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Cell and Structural Biology, B107 Chemical and Life Science Laboratory, 601 S. Goodwin, Urbana, IL 61801. Tel.: 217-244-4525; Fax: 217-244-1648; E-mail: j-george{at}uiuc.edu.

1 The abbreviations used are: NACP, non-amyloid component precursor; POPC, 1-palmitoyl 2-oleoyl phosphatidylcholine; POPA, 1-palmitoyl 2-oleoyl phosphatidic acid; POPS, 1-palmitoyl 2-oleoyl phosphatidylserine; POPE, 1-palmitoyl 2-oleoyl phosphatidylethanolamine; PI, phosphatidylinositol; PC, phosphatidylcholine; PA, phosphatidic acid; PS, phosphatidylserine; PE, phosphatidylethanolamine; SUV, small unilamellar vesicle; LUV, large unilamellar vesicle; MLV, multilamellar vesicle.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. George, J. M., Jin, H., Woods, W. S., and Clayton, D. F. (1995) Neuron 15, 361-372[Medline] [Order article via Infotrieve]
  2. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D., Kondo, J., Ihara, Y., and Saitoh, T. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11282-11286[Abstract]
  3. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehijia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Science 276, 2045-2047[Abstract/Free Full Text]
  4. Okazaki, H., Lipkin, L. E., and Aronson, S. M. (1961) J. Neuropathol. Exp. Neurol. 20, 237-244
  5. Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) Nature 388, 839-840[CrossRef][Medline] [Order article via Infotrieve]
  6. Withers, G., George, J., Banker, G., and Clayton, D. F. (1997) Dev. Brain Res. 99, 87-94[CrossRef][Medline] [Order article via Infotrieve]
  7. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H., Kittel, A., and Saitoh, T. (1995) Neuron 14, 467-475[Medline] [Order article via Infotrieve]
  8. Maroteaux, L., and Scheller, R. H. (1991) Mol. Brain Res. 11, 335-343[Medline] [Order article via Infotrieve]
  9. Jakes, R., Spillantini, M. G., and Goedert, M. (1994) FEBS Lett. 345, 27-32[CrossRef][Medline] [Order article via Infotrieve]
  10. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., and Lansbury, P. T., Jr. (1996) Biochemistry 35, 13709-13715[CrossRef][Medline] [Order article via Infotrieve]
  11. Schiffer, A., and Edmundson, A. B. (1967) Biophys. J. 7, 121-135[Medline] [Order article via Infotrieve]
  12. Segrest, J., De Loof, H., Dohlman, J., Brouillette, C., and Anantharamaiah, G. (1990) Proteins Struct. Funct. Genet. 8, 103-117[Medline] [Order article via Infotrieve]
  13. Segrest, J., Jones, M., De Loof, H., Brouillette, C., Venkatachalapathi, Y., and Anantharamaiah, G. (1992) J. Lipid Res. 33, 141-166[Abstract]
  14. Barenholz, Y., Gibbes, D., Litman, B. J., Goll, J., Thompson, T. E., and Carlson, R. D. (1977) Biochemistry 16, 2806-2810[Medline] [Order article via Infotrieve]
  15. Davidson, W. S., Rodrigueza, W. V., Lund-Katz, S., Johnson, W. J., Rothblat, G. H., and Phillips, M. C. (1995) J. Biol. Chem. 270, 17106-17113[Abstract/Free Full Text]
  16. Hope, M. J., Nayar, R., Mayer, L. D., and Cullis, P. R. (1993) in Liposome Technology (Gregoriadis, G., ed), pp. 123-139, CRC Press, Boca Raton, FL
  17. Markwell, M. A., Haas, S. M., Biever, L. L., and Tolbert, N. E. (1978) Anal. Biochem. 87, 206-210[Medline] [Order article via Infotrieve]
  18. Sokoloff, L., and Rothblat, G. H. (1974) Proc. Soc. Exp. Biol. Med. 146, 1166-1172
  19. Geourjon, C., and Deleage, G. (1993) Comp. Appl. Biosci. 9, 87-91[Abstract]
  20. Levin, J. M., and Garnier, J. (1988) Biochim. Biophys. Acta 955, 283-295[Medline] [Order article via Infotrieve]
  21. Garnier, J., Osguthorpe, D. J., and Robeson, B. (1978) J. Mol. Biol. 120, 97-120[Medline] [Order article via Infotrieve]
  22. Chou, P., and Fasman, G. (1978) Adv. Enzymol. 47, 45-148[Medline] [Order article via Infotrieve]
  23. Nolte, R. T., and Atkinson, D. (1992) Biophys. J. 63, 1221-1239[Abstract]
  24. Andrade, M. A., Chacon, P., Merelo, J. J., and Moran, F. (1993) Protein Eng. 6, 383-390[Abstract]
  25. Maroteaux, L., Campanelli, J. T., and Scheller, R. H. (1988) J. Neurosci. 8, 2804-2815[Abstract]
  26. Irizarry, M. C., Kim, T. W., McNamara, M., Tanzi, R. E., George, J. M., Clayton, D. F., and Hyman, B. T. (1996) J. Neuropathol. Exp. Neurol. 55, 889-895[Medline] [Order article via Infotrieve]
  27. Nakajo, S., Shioda, S., Nakai, Y., and Nakaya, K. (1994) Mol. Brain Res. 27, 81-86[Medline] [Order article via Infotrieve]
  28. Breckenridge, W. C., Morgan, I. C., Zanetta, J. P., and Vincendon, G. (1973) Biochim. Biophys. Acta 320, 681-686[Medline] [Order article via Infotrieve]
  29. Deutsch, J. W., and Kelly, R. B. (1981) Biochemistry 20, 378-385[Medline] [Order article via Infotrieve]
  30. Michaelson, D. M., Barkai, G., and Barenholz, Y. (1983) Biochem. J. 211, 155-162[Medline] [Order article via Infotrieve]
  31. Yang, L., and Glaser, M. (1995) Biochemistry 34, 1500-1506[Medline] [Order article via Infotrieve]
  32. Huang, C. (1969) Biochemistry 8, 344-352[Medline] [Order article via Infotrieve]
  33. Thomas, P. D., and Poznansky, M. J. (1988) Biochem. J. 254, 155-160[Medline] [Order article via Infotrieve]
  34. Letizia, J. Y., and Phillips, M. C. (1991) Biochemistry 30, 866-873[Medline] [Order article via Infotrieve]
  35. Palgunachari, M. N., Mishra, V. K., Lund-Katz, S., Phillips, M. C., Adeyeye, S. O., Alluri, S., Anantharamaiah, G. M., and Segrest, J. P. (1996) Arterioscler. Thromb. Vasc. Biol. 16, 328-338[Abstract/Free Full Text]
  36. Mishra, V. K., and Palgunachari, M. N. (1996) Biochemistry 35, 11210-11220[CrossRef][Medline] [Order article via Infotrieve]
  37. Nakajo, S., Tsukada, K., Omata, K., Nakamura, Y., and Nakaya, K. (1993) Eur. J. Biochem. 217, 1057-1063[Abstract]
  38. Borhani, D. W., Rogers, D. P., Engler, J. A., and Brouillette, C. G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12291-12296[Abstract/Free Full Text]
  39. Jonas, A., Kezdy, K. E., and Wald, J. H. (1989) J. Biol. Chem. 264, 4818-4824[Abstract/Free Full Text]
  40. Tytler, E., Segrest, J., Epand, R., Nie, S., Epand, R., Mishra, V., Venkatachalapathi, Y., and Anantharamaiah, G. (1993) J. Biol. Chem. 268, 22112-22118[Abstract/Free Full Text]
  41. Epand, R. M., Shai, Y., Segrest, J. P., and Anantharamaiah, G. M. (1995) Biopolymers 37, 319-338[Medline] [Order article via Infotrieve]
  42. Chen, Y. H., Yang, J. T., and Martinez, H. M. (1972) Biochemistry 11, 4120-4131[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.